Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Sarcoma, Myeloid 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Leukemia, Biphenotypic, Acute 1Blast Crisis 1

Interventions

venetoclax 2ruxolitinib 2fludarabine phosphate 2Sirolimus 2Leucovorin 2Immunoglobulin G 2Doxorubicin 2Disulfides 2Cyclophosphamide 2Bortezomib 2Bevacizumab 2Azacitidine 2vactosertib 1trametinib 1temsirolimus 1sargramostim 1regorafenib 1ponatinib 1pertuzumab 1pembrolizumab 1palbociclib 1olaparib 1neratinib 1lorlatinib 1lenvatinib 1idelalisib 1hydrocortisone sodium phosphate 1fludarabine 1enzalutamide 1entrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Dexrazoxane × Myeloid × Clear all
NCT05292664 2026-03-12

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Dana-Farber Cancer Institute

Phase 1 Recruiting
30 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasm Metastasis, Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡